Search

Your search keyword '"AstraZeneca PLC -- Product development"' showing total 3,534 results
Start Over Descriptor "AstraZeneca PLC -- Product development"
3,534 results on '"AstraZeneca PLC -- Product development"'

51. Non-Cystic Fibrosis Bronchiectasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring

Subjects
Boehringer Ingelheim GmbH -- Product development, AstraZeneca PLC -- Product development, Insmed Inc. -- Product development, Medical research, Medicine, Experimental, Cystic fibrosis, Clinical trials, Bronchiectasis, Business, Business, international
Abstract

M2 PRESSWIRE-September 24, 2024-: Non-Cystic Fibrosis Bronchiectasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring (C)1994-2024 M2 [...]

Published
2024

52. AIM ImmunoTech Reported Positive Preliminary Data in Phase 1b|2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Subjects
AstraZeneca PLC -- Product development, Oncology, Experimental, Cancer -- Research, Pancreatic cancer -- Care and treatment, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Ampligen (Medication) -- Product development, Imfinzi (Medication) -- Product development
Abstract

OCALA: AIM ImmunoTech Inc. (NYSE American: AIM) (AIM) today announced positive preliminary data from the Phase 1b/2 study (DURIPANC) evaluating the combination of AIM's Ampligen(r) (rintatolimod) and AstraZeneca's anti-PD-L1 immune [...]

Published
2024

53. IMFINZI(r) (durvalumab) plus IMJUDO(r) (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial

Subjects
AstraZeneca PLC -- Product development, Cancer patients -- Care and treatment -- Patient outcomes, Liver cancer -- Care and treatment -- Patient outcomes, Clinical trials -- Analysis, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary, Imjudo (Medication) -- Product development, Imfinzi (Medication) -- Product development
Abstract

WILMINGTON: ASTRAZENECA has issued the following news release: Updated results from the HIMALAYA Phase III trial showed AstraZeneca's IMFINZI(r) (durvalumab) plus IMJUDO(r) (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival [...]

Published
2024

54. AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Subjects
AstraZeneca PLC -- Product development, Oncology, Experimental, Cancer -- Research, Pancreatic cancer -- Care and treatment, Pharmaceutical industry -- Product development, Business, international, Ampligen (Medication) -- Product development, Imfinzi (Medication) -- Product development
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination of Ampligen and Imfinzi continues [...]

Published
2024

55. Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Subjects
Bayer AG -- Product development, Bristol-Myers Squibb Co. -- Product development, Boehringer Ingelheim GmbH -- Product development, Novartis AG -- Product development, AstraZeneca PLC -- Product development, Product development, Clinical trials, Riociguat, Business research, Treprostinil -- Product development, Nintedanib, Lung diseases, Pharmaceutical industry -- Product development, Pirfenidone, Business -- Research
Abstract

M2 PRESSWIRE-September 16, 2024-: Interstitial Lung Disease Clinical Trials 2024: FDA Approvals, Medication, Pipeline Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:15092024 Interstitial Lung [...]

Published
2024

56. Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Lung cancer, Small cell -- Patient outcomes -- Care and treatment, Clinical trials, Lung cancer, Non-small cell -- Care and treatment -- Patient outcomes, Pharmaceutical industry -- Product development, Business, international
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca's proprietary computational pathology [...]

Published
2024

57. Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Oncology, Experimental, Lung cancer, Small cell -- Patient outcomes -- Care and treatment, Chemotherapy, Clinical trials, Lung cancer, Non-small cell -- Care and treatment -- Patient outcomes, Cancer -- Chemotherapy -- Research, Pharmaceutical industry -- Product development, Business, international, Imfinzi (Medication) -- Product development
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab [...]

Published
2024

58. Novel Computational Pathology-Based TROP2 Biomarker for Datopotamab Deruxtecan Was Predictive of Clinical Outcomes in Patients with Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial

Subjects
AstraZeneca PLC -- Product development, Lung cancer, Small cell -- Patient outcomes -- Care and treatment, Lung cancer, Non-small cell -- Care and treatment -- Patient outcomes, Pharmaceutical industry -- Product development, General interest, News, opinion and commentary
Abstract

TOKYO & BASKING RIDGE: Daiichi Sankyo has issued the following news release: Results from an exploratory analysis of the TROPION-Lung01 phase 3 trial showed TROP2 as measured by quantitative continuous [...]

Published
2024

59. AstraZeneca drug for early lung cancer fails Phase 3 trial

Subjects
AstraZeneca PLC -- Product development, Lung cancer -- Drug therapy, Clinical trials, Pharmaceutical industry -- Product development, General interest, Imfinzi (Medication) -- Product development
Abstract

An AstraZeneca drug aimed at treating early stage lung cancer has failed its latest clinical trials. The Anglo-Swedish drug giant said Imfinzi, known as durvalumab, did not meet the main [...]

Published
2024

60. AstraZeneca's Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, stage III EGFR-mutated lung cancer in LAURA phase III trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Epidermal growth factor, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Tagrisso (Medication) -- Product development
Abstract

Positive high-level results from the LAURA phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, [...]

Published
2024

61. Positive high-level results from Japan phase III trial of acoramidis in adults with transthyretin-mediated ATTR-CM showed consistency with global ATTRibute-CM phase III trial

Subjects
Alexion Pharmaceuticals Inc. -- Product development, AstraZeneca PLC -- Product development, Clinical trials, Adults, Heart, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

Positive high-level results from the Japan phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency to those in the global BridgeBio Pharma, Inc. (BridgeBio) ATTRibute-CM [...]

Published
2024

62. Studies in the Area of Cervical Cancer Reported from University of Arizona [Durvalumab Versus Placebo With Chemoradiotherapy for Locally Advanced Cervical Cancer (Calla): a Randomised, Double-blind, Phase 3 Trial]

Subjects
AstraZeneca PLC -- Product development, Oncology, Experimental, Women -- Health aspects, Journalistic ethics -- Research, Cervical cancer -- Care and treatment -- Research, Clinical trials -- Research, Cancer -- Research, Pharmaceutical industry -- Product development, Health, Women's issues/gender studies, The University of Arizona
Abstract

2024 JAN 25 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in Oncology - Cervical Cancer. According to news reporting originating [...]

Published
2024

63. AIM ImmunoTech starts patient enrolment in phase 1b/2 study of Ampligen in combo with AstraZeneca's Imfinzi to treat late-stage pancreatic cancer

Subjects
AstraZeneca PLC -- Product development, Oncology, Experimental, Cancer -- Care and treatment -- Research, Clinical trials, Pancreatic cancer -- Care and treatment, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries, Ampligen (Medication) -- Product development, Imfinzi (Medication) -- Product development
Abstract

AIM ImmunoTech Inc., an immuno-pharma company, announced that the first subject has been enrolled at Erasmus Medical Center (Erasmus MC) in a phase 1b/2 clinical trial combining AIM's Ampligen (rintatolimod) [...]

Published
2024

64. Two phase 3 trials of Daiichi Sankyo & AstraZeneca's datopotamab deruxtecan plus durvalumab initiated in patients across two breast cancer subtypes

Subjects
AstraZeneca PLC -- Product development, Cancer patients, Biological products -- Product development, Chemotherapy, Cancer -- Chemotherapy, Breast cancer, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

The first patient has been dosed in two global, randomized phase 3 trials evaluating the efficacy and safety of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan (Dato-DXd) in combination with durvalumab, [...]

Published
2023

65. AstraZeneca to discontinue STABILIZE-CKD and DIALIZE-Outcomes phase III trials for Lokelma

Subjects
AstraZeneca PLC -- Product development, Biological products -- Product development, Clinical trials, Kidney diseases, Pharmaceutical industry -- Product development, Pharmaceuticals and cosmetics industries
Abstract

AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was made due to substantially increased enrolment timelines and low [...]

Published
2023

66. AstraZeneca: TEZSPIRE Met Both Co-primary Endpoints in the Phase III WAYPOINT Trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international, Telecommunications industry, Tezspire (Medication) -- Product development
Abstract

Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen's TEZSPIRE (tezepelumab) demonstrated a statistically [...]

Published
2024

67. Alexion, AstraZeneca Rare Disease and Merck Highlight Positive Topline Results from the Phase 3 KOMET Trial

Subjects
AstraZeneca PLC -- Product development, Merck Research Laboratories -- Product development, Diseases -- United States -- United Kingdom, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international, Telecommunications industry, Koselugo (Medication) -- Product development
Abstract

Alexion, AstraZeneca Rare Disease and Merck, known as MSD outside of the United States and Canada, reported positive topline results from the Phase 3 KOMET trial, which is the largest, [...]

Published
2024

68. AstraZeneca's Tezspire achieves positive results in nasal polyps trial

Subjects
AstraZeneca PLC -- Product development, Nasal polyps, Pharmaceutical industry -- Product development, Chemistry, Tezspire (Medication) -- Product development
Abstract

M2 PHARMA-November 8, 2024-AstraZeneca's Tezspire achieves positive results in nasal polyps trial (C)2024 M2 COMMUNICATIONS Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Friday that its [...]

Published
2024

69. AstraZeneca's Tezspire achieves positive results in nasal polyps trial

Subjects
AstraZeneca PLC -- Product development, Nasal polyps, Pharmaceutical industry -- Product development, Business, international, Tezspire (Medication) -- Product development
Abstract

NORDIC BUSINESS REPORT-November 8, 2024-AstraZeneca's Tezspire achieves positive results in nasal polyps trial (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Friday [...]

Published
2024

70. AstraZeneca's Tezspire achieves positive results in nasal polyps trial

Subjects
AstraZeneca PLC -- Product development, Nasal polyps, Pharmaceutical industry -- Product development, Business, Tezspire (Medication) -- Product development
Abstract

M2 EQUITYBITES-November 8, 2024-AstraZeneca's Tezspire achieves positive results in nasal polyps trial (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Friday that [...]

Published
2024

71. Reports Outline Clinical Trials and Studies Study Findings from AstraZeneca (Robustness Assessment of Oncology Dose-Finding Trials Using the Modified Fragility Index)

Subjects
AstraZeneca PLC -- Product development, Research, Reports, Product development, Clinical trials -- Research -- Reports, Medical research -- Reports, Pharmaceutical industry -- Product development, Medicine, Experimental -- Reports
Abstract

2024 NOV 4 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on clinical trials and studies is the subject of a new report. [...]

Published
2024

72. Findings on Respiratory Syncytial Viruses Reported by Investigators at AstraZeneca [Molecular and Phenotypic Characteristics of Respiratory Syncytial Virus Isolates Recovered From Medically Vulnerable Children: an Exploratory Analysis of a Phase ...]

Subjects
AstraZeneca PLC -- Product development, Palivizumab -- Research -- Product development, Heart diseases -- Research, Genetic disorders -- Research, Respiratory tract diseases -- Research, Infants (Newborn) -- Diseases, Clinical trials -- Research, Infants (Premature) -- Research, Pharmaceutical industry -- Product development, Health
Abstract

2024 OCT 28 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on RNA Viruses - Respiratory Syncytial Viruses have been presented. According to [...]

Published
2024

73. Researchers at QIMR Berghofer Medical Research Institute Report New Data on Clinical Trial Research (The Effect of Vitamin D Supplementation On Pain: an Analysis of Data From the D-health Randomised Controlled Trial)

Subjects
Novartis AG -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Alfacalcidol -- Product development, Calcifediol -- Product development, Vitamin D -- Product development, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Health
Abstract

2024 OCT 25 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Clinical Trial Research. According to news reporting originating [...]

Published
2024

74. eSource Interoperability Between EHR and EDC: Evidence from a Phase III cancer trial points to notable advances in data-transfer tech

Author

Sundgren, Mats, Wong, Wai Keong, Saleem, Nausheen, Taylor, Sarah, Fransson, Lars, Collins, Nick, Gustafsson, David, Forsby, Mikael, and Yeatman, Richard

Subjects
AstraZeneca PLC -- Product development, Medical research -- Analysis, Medicine, Experimental -- Analysis, Medical records -- Analysis, Clinical trials -- Analysis, Cancer -- Analysis, Electronic records -- Product development, Pharmaceutical industry -- Product development, General interest, Health
Abstract

In 2021, University College London Hospitals NHS Foundation Trust (UCLH), IgniteData, and AstraZeneca embarked on a ground-breaking collaboration to evaluate how electronic health record (EHR)-to-electronic data capture (EDC) data-transfer technology [...]

Published
2023

75. DHT RAMP-UP: PHARMA STEPS UP PURSUITS IN DIGITAL TECHNOLOGY

Subjects
Merck & Company Inc. -- Product development, McKinsey and Company Inc. -- Product development, Pfizer Inc. -- Product development, AstraZeneca PLC -- Product development, Sanofi S.A. -- Product development, Consulting services -- Product development, Pharmaceutical industry -- Product development, General interest, Health
Abstract

Christine Bahls Freelance Writer for Medical, Clinical Trials, and Pharma Information In the recent past, most Big Pharma companies used digital heath technology (DHT) on a project-by-project basis, or perhaps [...]

Published
2024

76. United Kingdom : Clinical trials for chronic kidney disease

Subjects
AstraZeneca PLC -- Product development, Medical research, Medicine, Experimental, Chronic kidney failure, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Product development
Abstract

Clinical trials to accelerate research into treating chronic kidney disease will be strengthened as a result of a new partnership between the Scottish Government, academia and industry. NHS Scotland, AstraZeneca [...]

Published
2024

77. Fixed-duration Calquence plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukaemia in AMPLIFY Phase III trial

Subjects
AstraZeneca PLC -- Product development, Clinical trials -- Analysis, Pharmaceutical industry -- Product development, Business, international, Calquence (Medication) -- Product development
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca's Calquence [...]

Published
2024

78. FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results

Subjects
United States. Food and Drug Administration, AstraZeneca PLC -- Product development, Lung cancer, Small cell -- Care and treatment, Clinical trials, Lung cancer, Non-small cell -- Care and treatment, Pharmaceutical industry -- Product development, Business, international, Imfinzi (Medication) -- Product development
Abstract

Cambridge, United Kingdom: AstraZeneca Pharmaceutical company has issued the following press release: The Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca's Imfinzi (durvalumab) met the [...]

Published
2024

79. Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight

Subjects
Bayer AG -- Product development, Bristol-Myers Squibb Co. -- Product development, Boehringer Ingelheim GmbH -- Product development, Novartis AG -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Lung diseases, Treprostinil -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 9, 2024-: Interstitial Lung Disease Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:09072024 Interstitial Lung [...]

Published
2024

80. Lupus Nephritis Pipeline Insights 2024: Therapies, Clinical Trials by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche, AstraZeneca

Subjects
Novartis Pharma AG -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Nephritis -- Reports, Lupus -- Reports, B cells -- Reports, Clinical trials -- Reports, Monoclonal antibodies -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 5, 2024-: Lupus Nephritis Pipeline Insights 2024: Therapies, Clinical Trials by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche, AstraZeneca (C)1994-2024 M2 COMMUNICATIONS RDATE:05072024 Las [...]

Published
2024

81. Cushing's Syndrome Pipeline Status 2024: Clinical Trials Overview and Therapeutic Landscape by DelveInsight | Crinetics Pharma, AstraZeneca, Novartis, Sparrow Pharma, Corcept Therapeutics

Subjects
Novartis AG -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Clinical trials -- Health aspects -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 5, 2024-: Cushing's Syndrome Pipeline Status 2024: Clinical Trials Overview and Therapeutic Landscape by DelveInsight | Crinetics Pharma, AstraZeneca, Novartis, Sparrow Pharma, Corcept Therapeutics (C)1994-2024 M2 COMMUNICATIONS RDATE:05072024 [...]

Published
2024

82. Pancreatic Ductal Adenocarcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Subjects
AstraZeneca PLC -- Product development, Adenocarcinoma -- Drug therapy, Drug approval -- Reports, Clinical trials -- Reports, Pancreatic cancer -- Drug therapy, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 4, 2024-: Pancreatic Ductal Adenocarcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:03072024 DelveInsight's, 'Pancreatic Ductal Adenocarcinoma Pipeline Insight 2024' [...]

Published
2024

83. HR Positive/ HER2 Negative Breast Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Eli Lilly, Laekna, Sermonix Pharma, BeiGene, Olema Pharma, AstraZeneca

Subjects
Daiichi Sankyo Inc. -- Product development, Stemline Therapeutics Inc. -- Product development, Seagen Inc. -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, Business -- Research, Biotechnology industry -- Product development, Cancer -- Care and treatment, Clinical trials -- Reports, Breast cancer -- Drug therapy, Fulvestrant -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 3, 2024-: HR Positive/ HER2 Negative Breast Cancer Pipeline Analysis 2024: FDA Approvals and Emerging Therapies by DelveInsight | Eli Lilly, Laekna, Sermonix Pharma, BeiGene, Olema Pharma, AstraZeneca [...]

Published
2024

84. Asthma Clinical Trials Analysis 2024: Therapies, FDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Subjects
Novartis AG -- Product development, AstraZeneca PLC -- Product development, Sanofi S.A. -- Product development, Business -- Research, Respiratory agents, Biological products -- Product development, Drug approval, Clinical trials, Pharmaceutical industry -- Product development, Asthma, Business, Business, international
Abstract

M2 PRESSWIRE-July 2, 2024-: Asthma Clinical Trials Analysis 2024: Therapies, FDA Approvals, Mechanism of Action, Route of Administration, and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:02072024 * Asthma companies are [...]

Published
2024

85. Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Subjects
Pfizer Inc. -- Product development, Boehringer Ingelheim GmbH -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, Business -- Research, Diseases -- Germany -- United States -- United Kingdom, Fatty liver, Clinical trials, Type 2 diabetes, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-July 2, 2024-: Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials Analysis 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS [...]

Published
2024

86. Soft Tissue Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Subjects
Bayer AG -- Product development, Takara Bio Inc. -- Product development, Incyte Corp. -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Sarcoma, Biotechnology industry -- Product development, Clinical trials, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 28, 2024-: Soft Tissue Sarcoma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:28062024 Soft Tissue Sarcoma [...]

Published
2024

87. Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Subjects
AstraZeneca PLC -- Product development, Business -- Research, Tumors -- Drug therapy, Drug approval -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 27, 2024-: Biliary Tumor Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:26062024 DelveInsight's, 'Biliary Tumor Pipeline Insight, 2024' report provides [...]

Published
2024

88. Mesothelioma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Subjects
Novartis Pharma AG -- Product development, AstraZeneca PLC -- Product development, Business -- Research, Ipilimumab -- Reports, Pemetrexed -- Product development, Mesothelioma -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 27, 2024-: Mesothelioma Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:27062024 Mesothelioma companies are UTC Therapeutics, [...]

Published
2024

89. Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer

Subjects
AstraZeneca PLC -- Product development, Imfinzi (Medication) -- Product development, Product development, Clinical trials, Durvalumab -- Product development, Small cell lung cancer, Pharmaceutical industry -- Product development, Non-small cell lung cancer, Lung cancer, Small cell, Lung cancer, Non-small cell
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group (CCTG), showed Imfinzi (durvalumab) [...]

Published
2024

90. Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

Subjects
AstraZeneca PLC -- Product development, Imfinzi (Medication) -- Product development, Care and treatment, Patient outcomes, Product development, Clinical trials, Durvalumab -- Product development, Bladder cancer -- Patient outcomes -- Care and treatment, Chemotherapy, Pharmaceutical industry -- Product development, Cancer patients -- Care and treatment -- Patient outcomes, Cancer -- Chemotherapy
Abstract

Cambridge, United Kingdom: AstraZeneca has issued the following press release: Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically [...]

Published
2024

91. IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

Subjects
AstraZeneca PLC -- Product development, Cancer patients -- Care and treatment -- Patient outcomes, Bladder cancer -- Complications and side effects -- Patient outcomes -- Care and treatment, Chemotherapy, Clinical trials, Cancer -- Chemotherapy, Pharmaceutical industry -- Product development, News, opinion and commentary, Imjudo (Medication) -- Complications and side effects -- Product development, Imfinzi (Medication) -- Complications and side effects -- Product development
Abstract

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 25, 2024-- Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful [...]

Published
2024

92. AstraZeneca disappointed by breast cancer drug trial results

Subjects
AstraZeneca PLC -- Product development, Breast cancer -- Drug therapy, Pharmaceutical industry -- Product development, Business, international, Truqap (Medication) -- Product development
Abstract

London: AstraZeneca PLC has issued the following press release: AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints. [...]

Published
2024

93. Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer

Subjects
AstraZeneca PLC -- Product development, Metastasis, Chemotherapy, Clinical trials, Cancer -- Chemotherapy, Breast cancer, Pharmaceutical industry -- Product development, Business, international, Truqap (Medication) -- Product development
Abstract

Cambridge: AstraZeneca PLC (AZNCF) has issued the following press release: The CAPItello-290 Phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic [...]

Published
2024

94. Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna

Subjects
AstraZeneca PLC -- Product development, Business -- Research, Squamous cell carcinoma -- Drug therapy, Clinical trials -- Reports, Drug approval -- Reports, Epigenetic inheritance -- Reports, Monoclonal antibodies -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 19, 2024-: Squamous Cell Carcinoma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA | Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, VCN Biosciences, Moderna (C)1994-2024 [...]

Published
2024

95. Update on CAPItello-290 Phase III trial

Subjects
AstraZeneca PLC -- Product development, Metastasis, Clinical trials, Pharmaceutical industry -- Product development, Business, international, Truqap (Medication) -- Product development
Abstract

Helsinki: AstraZeneca PLC has issued the following news release: The CAPItello-290 Phase III trial for Truqap (capivasertib) in combination with paclitaxel in patients with locally advanced (inoperable) or metastatic triple-negative [...]

Published
2024

96. Leptomeningeal Metastases Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Subjects
AstraZeneca PLC -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Business -- Research, Metastasis -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 18, 2024-: Leptomeningeal Metastases Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight (C)1994-2024 M2 COMMUNICATIONS RDATE:18062024 As per [...]

Published
2024

97. Advanced Kidney Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Subjects
AstraZeneca PLC -- Product development, Business -- Research, Kidney cancer -- Reports, Antineoplastic agents -- Product development, Drugs -- Product development, Clinical trials -- Reports, Drug approval -- Reports, Cancer -- Reports, Pharmaceutical industry -- Product development, Antimitotic agents -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 18, 2024-: Advanced Kidney Cancer Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies (C)1994-2024 M2 COMMUNICATIONS RDATE:17062024 DelveInsight's, 'Advanced Kidney Cancer Pipeline Insight [...]

Published
2024

98. CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

Subjects
AstraZeneca PLC -- Product development, Non-Hodgkin's lymphomas -- Complications and side effects -- Care and treatment, Clinical trials, Bendamustine -- Complications and side effects, Pharmaceutical industry -- Standards -- Product development, News, opinion and commentary, Calquence (Medication) -- Complications and side effects -- Product development
Abstract

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 16, 2024-- Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically [...]

Published
2024

99. Peritoneal Cancer Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck, AstraZeneca

Subjects
Bristol-Myers Squibb Co. -- Product development, Pfizer Inc. -- Product development, ImmunoGen Inc. -- Product development, AstraZeneca PLC -- Product development, Medical research -- Health aspects -- Reports, Medicine, Experimental -- Health aspects -- Reports, Antigens -- Reports -- Health aspects, Clinical trials -- Health aspects -- Reports, Cancer -- Drug therapy, Fulvestrant -- Product development, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 14, 2024-: Peritoneal Cancer Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, ImmunoGen, OncoQuest, OncXerna Therapeutics, Merck, AstraZeneca (C)1994-2024 M2 [...]

Published
2024

100. Diabetic Neuropathic Pain Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies by DelveInsight |Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca

Subjects
Lexicon Pharmaceuticals Inc. -- Product development, AstraZeneca PLC -- Product development, Eli Lilly and Co. -- Product development, Medical research -- Reports, Medicine, Experimental -- Reports, Clinical trials -- Reports, Pain -- Care and treatment, Pharmaceutical industry -- Product development, Business, Business, international
Abstract

M2 PRESSWIRE-June 13, 2024-: Diabetic Neuropathic Pain Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies by DelveInsight |Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca (C)1994-2024 M2 [...]

Published
2024

Catalog

Books, media, physical & digital resources
See catalog results